Lysophosphatidic acid receptor 6 is a potential biomarker associated with lung adenocarcinoma
作者单位：上海交通大学医学院
会议名称：《2021年中国肿瘤标志物学术大会暨第十五届肿瘤标志物青...》
会议日期：2021年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
关 键 词：LPAR6 tumor infiltration lymphocytes prognosis lung adenocarcinoma biomarker
摘 要：LPAR6 is the most recently determined G-protein-coupled receptor of lysophosphatidic acid receptor, and very few of study have demonstrated the performance of LPAR6 in cancers. Moreover, the relationship of LPAR6 to the potential of prognosis and tumor infiltration immune cells in different types of cancer is still unclarified. The mR NA expression of LPAR6 and its clinical characteristics were evaluated on various databases. The association between LPAR6 and immune infiltrates of various types of cancer were investigated via TIMER. IHC for LPAR6 in lung adenocarcinoma（LUAD） and lung squamous cell carcinoma（LUSC） tissue microarray with patients’ information was detected. We constructed a systematic prognostic landscape in a variety types of cancer base on the expression level of mRNA. We enclosed that higher LPAR6 mR NA expression level was associated with better overall survival in some types of malignancy. Moreover, LPAR6 significantly affects the prognostic potential of various cancers in TCGA, especially in lung cancer. Tissue microarray’s results demonstrated that a higher protein level of LPAR6 was correlated to better overall survival of LUAD rather than LUSC cohorts. Further research found that the underlying mechanism of this phenome might be the mR NA expression level of LPAR6 was positively associated to infiltrating statuses of devious immunocytes in LUAD rather than in LUSC, that is, LPAR6 expression potentially contributes to the activation and recruiting of T cells（CD8+ T, naive T, effector T cell） and NK cells and inactivates Tregs, decrease T cell exhaustion and regulate T-helper cells in LUAD. Our discovery implies that LPAR6 is associated with prognostic potential and immune-infiltrating levels in *** discoveries imply that LPAR6 could be a novel promising biomarker for indicating the prognosis potential of LUAD patients.